In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B-Reference-Cited by-同舟云学术

In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B

Published:2000-02 Issue:2 Volume:44 Page:441-443
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Moore Caroline B.¹,Walls Caroline M.¹,Denning David W.²³⁴

Affiliation:

1. Departments of Microbiology1 and

2. Medicine,2 Hope Hospital, Salford, and

3. Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital,3 and

4. University of Manchester,4Manchester, United Kingdom

Abstract

ABSTRACT The in vitro activity of BMS-207147 against 80 clinical isolates of Aspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in μg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to >16 μg/ml. Aspergillus fumigatus was significantly more susceptible to BMS-207147 ( P < 0.05) than A. terreus and A. flavus . No BMS-207147-resistant A. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, >8 μg/ml) isolates were. BMS-207147 is active against Aspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.44.2.441-443.2000

Reference14 articles.

1. Itraconazole for experimental pulmonary aspergillosis—comparison with amphotericin-B, interaction with cyclosporin-A, and correlation between therapeutic response and itraconazole concentrations in plasma.;Berenger J.;Antimicrob. Agents Chemother.,1994

2. Invasive aspergillosis in immunocompromised patients.;Denning D. W.;Curr. Opin. Infect. Dis.,1994

3. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome for Aspergillus fumigatus infection.;Denning D. W.;J. Antimicrob. Chemother.,1997

4. Invasive aspergillosis.;Denning D. W.;Clin. Infect. Dis.,1998

5. In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the intersection of Aspergillus fumigatus biofilms, infections, immune response and antifungal resistance;Mycoses;2023-05-22

2. The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda;Fungal Biology Reviews;2020-12

3. Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications;Handbook of Antimicrobial Resistance;2017

4. Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis;Medical Mycology Journal;2016

5. Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans;Revista Iberoamericana de Micología;2015-01